SAN DIEGO & NEW YORK--(BUSINESS WIRE)--Aethlon Medical, Inc. (OTCBB:AEMD), a pioneer in developing therapeutic devices for infectious disease and advanced blood filtration, and Delcath Systems, Inc. (NASDAQ:DCTH), a development stage company focused on developing and marketing a proprietary drug delivery system, today announced a collaboration to jointly research and develop an advanced filtration cartridge for potential use in Delcath Systems’ percutaneous hepatic perfusion (“PHP”) system. PHP is a technology designed to isolate and deliver high doses of anti-cancer agents to specific organs or regions of the body, while minimizing the exposure of the drugs to the rest of the body.
